Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux Obtains CE Mark for VIDAS 3, Plans to Pursue US FDA Approval


BioMérieux said that its VIDAS 3 immunoassay platform has received an EU CE mark, making it commercially available in Europe and other countries recognizing the CE marking.

In a statement, François Lacoste, corporate vice president of BioMérieux's immunoassay unit, said the company now plans to pursue regulatory approval for the platform in other countries – the US and China, in particular.

The VIDAS 3 is the latest in BioMérieux's VIDAS line and, the company said, offers enhanced automation, improved traceability, and new software features, as well as a quality control program that is in compliance with laboratory certification standards.

Using the same reagents as previous VIDAS instruments, the device currently offers tests for 99 clinical parameters.

According to BioMérieux, the VIDAS line has the largest installed base of automated immunoassay systems in the world, with more than 27,000 instruments in clinical labs. The company claims that it has received roughly 200 intentions to purchase the new instrument based on recent conference demonstrations.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.